![Yoshinori Oikawa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Yoshinori Oikawa currently works at MyBiotics Pharma Ltd., as Executive Chairman and Emendo Biotherapeutics, Inc., as Director.
Actieve functies van Yoshinori Oikawa
Bedrijven | Functie | Begin |
---|---|---|
Emendo Biotherapeutics, Inc.
![]() Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
MyBiotics Pharma Ltd.
![]() MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | Voorzitter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Emendo Biotherapeutics, Inc.
![]() Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Health Technology |
MyBiotics Pharma Ltd.
![]() MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | Health Technology |